<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Two adolescents with <z:hpo ids='HP_0011009'>acute</z:hpo> B-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (Burkitt <z:hpo ids='HP_0001909'>leukemia</z:hpo>) had <z:hpo ids='HP_0011009'>acute</z:hpo> severe neurotoxicity after treatment with intrathecal (IT) <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (AraC) at a dose of 50 mg/day for three consecutive days </plain></SENT>
<SENT sid="1" pm="."><plain>RESULTS: A 16-year-old boy had a rapidly ascending <z:hpo ids='HP_0002196'>myelopathy</z:hpo> and <z:hpo ids='HP_0001298'>encephalopathy</z:hpo> 20 hours after receiving the third dose of IT AraC </plain></SENT>
<SENT sid="2" pm="."><plain>He remained quadriplegic and required ventilatory assistance for 10 months until his <z:hpo ids='HP_0011420'>death</z:hpo> from progressive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A 12-year-old girl had <z:hpo ids='HP_0006846'>acute encephalopathy</z:hpo>, <z:hpo ids='HP_0001250'>seizures</z:hpo>, and focal neuroimaging abnormalities in the cerebellum and brain stem within 32 hours of the third AraC dose and 8 hours after IT <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX, 12 mg) </plain></SENT>
<SENT sid="4" pm="."><plain>Her clinical neurologic deficits resolved during the ensuing month </plain></SENT>
<SENT sid="5" pm="."><plain>Patient 1 represents the first report to the authors' knowledge of <z:hpo ids='HP_0011009'>acute</z:hpo> severe neurotoxicity after AraC administered as the only IT drug </plain></SENT>
<SENT sid="6" pm="."><plain>In Patient 2, IT AraC neurotoxicity may have been potentiated by the single dose of MTX </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: IT AraC administered for 3 or more consecutive days may lead to profound neurologic dysfunction and require discontinuation of therapy </plain></SENT>
</text></document>